Sartorius AG (FWB: SRT), a German pharmaceutical and laboratory equipment provider, has expanded with the acquisition of a medical device company and a digital health company for a combined total of $392.5 million. Sartorius operates through two divisions: bioprocess solutions and lab products & services.
On March 3, 2017, Sartorius acquired privately-held Essen BioScience Inc. from SFW Capital Partners for $320 million. Essen develops and manufactures instruments, software, reagents and consumables which enable researchers to remotely image and quantify a wide variety of cellular processes over time.
Through this acquisition, Sartorius significantly expands its portfolio for bioanalytics, a field it entered via the IntelliCyt acquisition in 2016. Essen is expected to generate sales revenue of $60 million in 2017. Essen will be integrated with Sartorius’ lab products & services division.
In April, Sartorius acquired Swiss-based Umetrics Inc. from MKS Instruments, Inc. (NASDAQ: MKSI) for $72.5 million. Umetrics specializes in data analytics software for modeling and optimizing biopharmaceutical development and manufacturing processes, and the transaction was effected through Sartorius’ subgroup, Sartorius Stedim Biotech. Umetrics will be assimilated into Satorius’ bioprocess solutions division.
Sartorius management projects that, following the acquisitions, sales in the lab products & services division will increase by about 20% to 24% (previously about 6% to 10%), and sales in the bioprocess solutions division will grow by about 9% to 13%.
